Preprint / Version 1

Parathyroid Hormone Related Protein in Hypercalcemia Malignancies

Authors

  • Fadel Fikri Suharto Internal Medicine Medical Faculty Sriwijaya University
  • Yenny Dian Andayani Internal Medicine Medical Faculty Sriwijaya University

DOI:

https://doi.org/10.21467/preprints.592

Abstract

Background: Paraneoplastic syndromes encompass symptoms or signs caused by malignant tumors through humoral factors, such as hormones or cytokines, produced by tumor cells. Hypercalcemia is a common occurrence in cancer patients, particularly associated with Parathyroid Hormone-related Protein (PTHrP). PTHrP mimics parathyroid hormone (PTH) activity, leading to excessive bone resorption, hypocalcemia, and significant metabolic complications. 

Discussion: PTHrP plays a key role in malignancy-associated hypercalcemia, which is more acute and severe compared to primary hyperparathyroidism. PTHrP is produced by various tumors, including squamous cell carcinomas and breast adenocarcinomas, as well as some hematologic malignancies. Beyond its extracellular role in bone resorption, PTHrP also exerts intracellular effects through nuclear activities, influencing cell proliferation and apoptosis. Management of hypercalcemia prioritizes patient hydration, bisphosphonate use, and targeted therapies to mitigate PTHrP effects. Emerging treatments, such as monoclonal antibodies against PTHrP and osteoprotegerin, show potential for rapid calcium control. 

Conclusion: PTHrP is a critical biomarker in malignancy-associated hypercalcemia, reflecting its central role in calcium metabolism regulation and as a promising target for innovative therapies. Prompt management of this condition can enhance patients' quality of life and reduce the risk of severe complications.

Keywords:

paraneoplastic syndrome, hypercalcemia, parathyroid hormone related protein

Downloads

References

Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol. 2019;36(4):204–210. doi:https://doi.org/10.1053/j.semdp.2019.01.002

Robbins SL; Kumar VK. Neoplasia. Elsevier Saunders; 2013.

Lancaster E. Paraneoplastic Disorders. Continuum (N Y). 2017;23(6):1653–1679.

Chan AM, Baehring JM. Paraneoplastic neurological syndromes: a single institution 10-year case series. J Neurooncol. 2019;141(2):431–439. doi:10.1007/s11060-018-03053-3

Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education; 2022.

Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DSA. PTHrP-Mediated Hypercalcemia: Causes and Survival in 138 Patients. J Clin Endocrinol Metab. 2015;100(5):2024–2029. doi:10.1210/jc.2014-4250

Moe SM. Disorders Involving Calcium, Phosphorus, and Magnesium. Prim Care Clin Off Pract. 2008;35(2):215–237. doi:https://doi.org/10.1016/j.pop.2008.01.007

Tinawi M. Disorders of Calcium Metabolism: Hypocalcemia and Hypercalcemia. Cureus. 2021;13(1):e12420. doi:10.7759/cureus.12420

Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab. 2019;51(12):770–778. doi:10.1055/a-1049-0647

Goltzman D. Nonparathyroid hypercalcemia. Parathyr Disord. 2019;51:77–90.

In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education; 2022.

Hoftberger R; Rosenfeld MR; Dalmau J. Update on Neurological Paraneoplastic Syndromes. Curr Opin Oncol. 2015;27(6):489–495.

Horn L; Araujo L; Nana P; et al. Principles and Practice of Oncology. McGraw-Hill Education; 2015.

Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020;12(3):e7186. doi:10.7759/cureus.7186

Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197–223.

Dimitriadis GK, Angelousi A, Weickert MO, et al. Paraneoplastic endocrine syndromes. Soc Endocrinol. 2017;24(6):173–190.

van Sonderen A, Wirtz PW, Verschuuren JJGM, Titulaer MJ. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurol. 2013;15(2):224–239. doi:10.1007/s11940-012-0213-6

Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516–524. doi:10.1001/jama.2016.19699

Yasir M, Mechanic OJ. Syndrome of Inappropriate Antidiuretic Hormone Secretion. StatPearls Publ. Published online 2020. https://www.ncbi.nlm.nih.gov/books/NBK507777/

Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab. 2012;97(9):2947–2956. doi:10.1210/jc.2012-2142

Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713–722. doi:10.1210/jc.2013-3382

Mulatero P, Rabbia F, Veglio F. Paraneoplastic hyperaldosteronism associated with non-Hodgkin’s lymphoma. N Engl J Med. 2001;344(20):1558–1559. doi:10.1056/NEJM200105173442017

Khan F, Kleppel H, Meara A. Paraneoplastic Musculoskeletal Syndromes. Rheum Dis Clin North Am. 2020;46(3):577–586. doi:10.1016/j.rdc.2020.04.002

Downloads

Posted

2024-12-07

Section

Preprints

Categories